MEDIA RELEASE Investment marks latest step in strategic plan to capture significant part of unprecedented biosimilar patent-expiry market opportunity of USD 222 billion over next 10 yearsOngoing investment in in-house manufacturing to create end-to-end leading European biosimilar hub, capital expenditure commitments remain unchangedMost recent USD 440 million investment in new production plant in Brnik, due to open in 2028, brings total planned investment in Slovenia to more than USD 1.1 billion by 2029 Bas ...